Triple Class Refractory Myeloma

Chair(s)

• 

  Philippe Moreau, MD

  Head of Hematology
  University Hospital Hôtel-Dieu, Nantes, France
  Nantes, Pays de la Loire, France

Co-Chair(s)

• 

  Sagar Lonial, MD, FACP

  Professor and Chair
  Emory University School of Medicine, Atlanta, GA, USA
  Atlanta, Georgia, United States

Presentations:

• 3:00 PM – 3:10 PM EEST

  How should we define refractoriness in myeloma?
  

  Speaker: Nizar J. Bahlis, MD – Arnie Charbonneau Cancer Institute - University of Calgary
• 3:10 PM – 3:20 PM EEST

  Molecular determinants of drug resistance
  

  Speaker: Lawrence Boise, PhD (he/him/his) – Emory University
• 3:20 PM – 3:30 PM EEST

  Role of tumor microenvironment in drug resistance
  

  Speaker: Suzanne Lentzsch, MD, PhD (she/her/hers) – Columbia University
• 3:30 PM – 3:40 PM EEST

  Non-Immune therapy for TCR
  

  Speaker: Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra
• 3:40 PM – 3:50 PM EEST

  OA-06: Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform
  

  Speaker: Shuntaro Ikegawa, MD, PhD – Dana-Farber Cancer Institute
• 3:50 PM – 4:00 PM EEST

  OA-23: Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis
  

  Speaker: Alexandra M. Poos, PhD (she/her/hers) – Multiple Myeloma Section, Department of Medicine V, University Hospital Heidelberg
• 4:00 PM – 4:10 PM EEST

  OA-24: Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing
  

  Speaker: Leo Rasche, MD – Department of Internal Medicine II, University Hospital, 97080 Würzburg, Germany
• 4:15 PM – 4:30 PM EEST

  Discuss abstracts in context
  

  Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
• 4:30 PM – 5:00 PM EEST

  Round table discussion
  

  Panelist: P. Joy Ho, MBBS DPhil FRACP FRCPA (she/her/hers) – Institute of Haematology, Royal Prince Alfred Hospital

  Panelist: Keith Stewart, MB ChB – Princess Margaret Cancer Centre, University Health Network

  Panelist: MELETIOS DIMOPOULOS, MD (he/him/his) – Department of Clinical Therapeutics/Medical School/National and Kapodistrian University of Athens

  Panelist: Donna E. Reece, MD – University Health Network, Princess Margaret Cancer Centre

  Panelist: Ajai Chari, MD, PhD – University of California, San Francisco

  Panelist: Bindu Kanapuru